Research conducted by Grossmann et al. indicated that expression of CEBPA is lower in AML (acute myeloid leukemia) patients with mutated RUNX1 (Runt Related Transcription Factor 1) gene13. This evidence concerns the gene RUNX1 and acute myeloid leukemia.